183 related articles for article (PubMed ID: 34203454)
1. Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes.
Martínez-Valiente C; Garcia-Ruiz C; Rosón B; Liquori A; González-Romero E; Fernández-González R; Gómez-Redondo I; Cervera J; Gutiérrez-Adán A; Sanjuan-Pla A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203454
[TBL] [Abstract][Full Text] [Related]
2. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
Kim SP; Srivatsan SN; Chavez M; Shirai CL; White BS; Ahmed T; Alberti MO; Shao J; Nunley R; White LS; Bednarski J; Pehrson JR; Walter MJ
Cell Rep; 2021 Aug; 36(9):109626. PubMed ID: 34469727
[TBL] [Abstract][Full Text] [Related]
3. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
Fei DL; Zhen T; Durham B; Ferrarone J; Zhang T; Garrett L; Yoshimi A; Abdel-Wahab O; Bradley RK; Liu P; Varmus H
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10437-E10446. PubMed ID: 30322915
[TBL] [Abstract][Full Text] [Related]
4. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
[TBL] [Abstract][Full Text] [Related]
5. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
6. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
7. Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor-Mutant Neoplasms.
Wheeler EC; Vora S; Mayer D; Kotini AG; Olszewska M; Park SS; Guccione E; Teruya-Feldstein J; Silverman L; Sunahara RK; Yeo GW; Papapetrou EP
Cancer Discov; 2022 Mar; 12(3):836-855. PubMed ID: 34620690
[TBL] [Abstract][Full Text] [Related]
8. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
9. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
10. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice.
Garcia-Ruiz C; Martínez-Valiente C; Cordón L; Liquori A; Fernández-González R; Pericuesta E; Sandoval J; Cervera J; Gutiérrez-Adán A; Sanjuan-Pla A
Leukemia; 2022 Oct; 36(10):2509-2518. PubMed ID: 36030305
[TBL] [Abstract][Full Text] [Related]
12. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
Graubert TA; Shen D; Ding L; Okeyo-Owuor T; Lunn CL; Shao J; Krysiak K; Harris CC; Koboldt DC; Larson DE; McLellan MD; Dooling DJ; Abbott RM; Fulton RS; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Grillot M; Baty J; Heath S; Frater JL; Nasim T; Link DC; Tomasson MH; Westervelt P; DiPersio JF; Mardis ER; Ley TJ; Wilson RK; Walter MJ
Nat Genet; 2011 Dec; 44(1):53-7. PubMed ID: 22158538
[TBL] [Abstract][Full Text] [Related]
13. Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms.
Wedge E; Ahmadov U; Hansen TB; Gao Z; Tulstrup M; Côme C; Nonavinkere Srivatsan S; Ahmed T; Jespersen JS; Schlotmann BC; Schöllkopf C; Raaschou-Jensen K; Ødum N; Kjems J; Bak RO; Walter MJ; Grønbæk K; Kristensen LS
Leukemia; 2023 May; 37(5):1113-1125. PubMed ID: 36922625
[TBL] [Abstract][Full Text] [Related]
14. Decreased CD177
Alayed K; Meyerson HJ
Leuk Res; 2022 Jan; 112():106752. PubMed ID: 34896936
[TBL] [Abstract][Full Text] [Related]
15. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
[TBL] [Abstract][Full Text] [Related]
16. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
[TBL] [Abstract][Full Text] [Related]
17. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
18. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
[TBL] [Abstract][Full Text] [Related]
19. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
20. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
Akef A; McGraw K; Cappell SD; Larson DR
PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]